The Lancet · Online· Zuzana Motovska, Ota Hlinomaz, Jan Mrozek, Ibrahim Akin, Petr Kala, Gilles Montalescot, Milan Hromadka, Tobias Geisler, Jan Precek, Jiri Kettner, Pavel Cervinka, Stanislav Katina, Jan Pudil, Christoph B Olivier, Josef Bis, Jan Matejka, Stanislaw Bartus, Jiri Jarkovsky, Alexandra Vodzinska, Pavol Tomasov, Ahmad Zohoor, Andrea Andrasova, Ales Kovarik, Janusz Kochman, Lenka Souckova, Petr Tousek, Ivan Vulev, Jacek Kubica, Petr Ostadal, Gregory Ducrocq, Zdenek Coufal, Richard Rokyta, Iuri Marinov, Regina Demlova, Michal Karpisek, Zdenek Klimsa, Martin Hudec, Petr Widimsky, Deepak L Bhatt, DAPT-SHOCK-AMI study group·· 12 小时前
DAPT-SHOCK-AMI 随机双盲试验：急性心肌梗死合并心源性休克患者中 Cangrelor 与碾碎替格瑞洛比较，30 天主要终点非劣效未成立
[Articles] Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial
AI 导读
DAPT-SHOCK-AMI 随机双盲试验在急性心肌梗死合并心源性休克（AMI-CS）患者中比较 Cangrelor 与碾碎替格瑞洛两种 P2Y12 抑制策略。结果显示，主要 PCI 结束时 Cangrelor 达到有效血小板抑制的比例更高，但 30 天临床主要终点未证实其相对碾碎替格瑞洛的非劣效。作者称这是该人群首个此类随机试验，结果可为未来 P2Y12 抑制策略研究提供依据。
来源：The Lancet · Online · thelancet.com